TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021
TRACON Pharmaceuticals (NASDAQ:TCON) will release its Q2 2021 financial results after U.S. markets close on August 11, 2021. The company is focused on developing targeted cancer therapeutics and operates a cost-efficient, CRO-independent platform for partnerships in the U.S. and abroad. A conference call will follow to discuss these results and corporate updates. The company is advancing its clinical pipeline, which includes key products like Envafolimab and TRC102. For further details, visit TRACON's website.
- The company is advancing its clinical pipeline with promising products.
- TRACON is actively seeking corporate partnerships to enhance U.S. commercialization.
- None.
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
| Conference call and webcast: | |
| Date: | August 11, 2021 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 3067769 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | (212) 915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
When will TRACON Pharmaceuticals report its Q2 2021 financial results?
What should investors expect during TRACON's conference call?
What is the focus of TRACON Pharmaceuticals?
